A long-term study of people with a history of drug use found that more people who have been vaccinated (PWID) are receiving treatment for Hepatitis C (HCV), which is associated with a significant reduction in liver disease and mortal. According to the authors, ongoing testing, treatment, and community intervention could move the United States closer to the 2030 HCV eradication goal of the World Health Organization (WHO) and the Department of Health and Human Services. The American Human Rights Society (HHS) plans for the next decade. . The survey results are published in Annals of Internal Medicine.
HCV can be cured for 95% of cases. The challenge is to identify people in the HCV-infected community and integrate them with care and treatment. In large regions like the United States, the majority of people infected with HCV are PWID who face systemic barriers to both HCV testing and treatment. They also have an undesirable side effect of diseases, such as HIV and alcohol abuse, which can alter the effect of HCV treatment on mortality.
Researchers from Johns Hopkins Bloomberg School of Public Health surveyed 1,323 participants enrolled in the LIVE (AIDS Linked to the IntraVenous Experience) study from 2006 to 2019 in Baltimore, Maryland to determine whether PWID was able to perform use all oral HCV treatments and if those treatments are reduced. liver disease and mortality. All study participants were diagnosed with chronic HCV infection. They were tested for HCV RNA annually from 2006 to 2012 and annually from 2014 to 2019.
The researchers found that the number of participants receiving HCV RNA decreased significantly from 100% of participants in 2006 to 48% in 2019, representing a significant increase in treatment. At the same time, they observed a strong association between this reduction of HCV RNA and liver disease. During this period, cirrhosis decreased from being in 15% of participants in 2006 and 8% in 2019.
According to the authors, given that 48% of the sample participants were chronically infected, their study also showed different types of treatment between PWIDs and the importance of overcoming these barriers to eliminate HCV infection in the United States. They also added that because the goal is to reduce mortality by 65 percent by 2030 depending on 2015, progress towards achieving this goal must include data on HCV outbreaks collected before 2015.
The Effect of Treating Hepatitis C on Cirrhosis and Deaths in Immunizations, Annals of Internal Medicine (2022). DOI: 10.7326 / M21-3846
American College of Medicine
hint: Getting hep C reduces disease and mortality among vaccinated people (2022, July 11) Retrieved 11 July 2022 from https://medicalxpress.com/news/2022-07-access -hep-treatment-morbidity-mortality. html
This document is copyrighted. Apart from any genuine transaction for research or investigation purposes, a section may not be reproduced without written permission. Content is provided for informational purposes only.
Access to hep C treatment reducing morbidity and mortality among people who inject drugs Source link Access to hep C treatment reducing morbidity and mortality among people who inject drugs